VKTX - Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape

2024-06-05 09:00:17 ET

Summary

• Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo.
• Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting.
• The financial outlook is stable with over three years of cash runway.
• Hold recommendation for GPCR stock; GSBR-1290 has potential, but competition and adverse effects warrant caution.

Structure Therapeutics Overview

Structure Therapeutics Inc. ( GPCR ) was in the news yesterday after a Phase 2a (randomized, placebo-controlled) obesity study of their "orally available, small-molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor," GSBR-1290, caused statistically significant placebo-adjusted mean weight loss after 12 weeks. The company is targeting an obesity treatment market that is expected to reach $130 billion in 2030. Current leaders, Novo Nordisk ( NVO ) and Eli Lilly ( LLY ), offer subcutaneous GLP-1 agonists, Wegovy and Zepbound (GLP-1 and GIP), respectively....

For further details see: